Literature DB >> 27613003

CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.

Geetika Bhatt1, Kami Maddocks1, Beth Christian2.   

Abstract

Evolution of cancer therapeutics has resulted in the development of agents with varying mechanisms of selective target inhibition. One such therapeutic approach is utilizing antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic agent in order to maximize efficacy with fewer toxicities. This review focuses on CD30 as a therapeutic target and the development and clinical activity of the ADC brentuximab vedotin in Hodgkin lymphoma (HL) and other B cell lymphomas.

Entities:  

Keywords:  Antibody-drug conjugate; Brentuximab vedotin; Hodgkin lymphoma; Non-Hodgkin lymphoma

Mesh：

Substances：

Year:  2016        PMID： 27613003     DOI： 10.1007/s11899-016-0345-y

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  73 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.

Authors: 
Journal:  Clin Adv Hematol Oncol       Date:  2016-02

Review 3.  Peripheral neuropathy induced by microtubule-stabilizing agents.

Authors:  James J Lee; Sandra M Swain
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

4.  The TNF receptor family member CD30 is not essential for negative selection.

Authors:  A L DeYoung; O Duramad; A Winoto
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

5.  Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors:  Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

6.  Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.

Authors:  Friederike Heuck; Julia Ellermann; Peter Borchmann; Achim Rothe; Hinrich Hansen; Andreas Engert; Elke Pogge von Strandmann
Journal:  J Immunother       Date:  2004 Sep-Oct       Impact factor: 4.456

7.  CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Wenli Zheng; L Jeffrey Medeiros; Ying Hu; Linda Powers; Jorge E Cortes; Farhad Ravandi-Kashani; Hagop H Kantarjian; Sa A Wang
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-01-10

8.  The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Authors:  Alan F Wahl; Kerry Klussman; Jennifer D Thompson; Judy H Chen; Leigh V Francisco; Grant Risdon; Dana F Chace; Clay B Siegall; Joseph A Francisco
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

9.  PML-IRIS in a patient treated with brentuximab.

Authors:  Gloria von Geldern; Carlos A Pardo; Peter A Calabresi; Scott D Newsome
Journal:  Neurology       Date:  2012-10-31       Impact factor: 9.910

10.  Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

Authors:  Nancy L Bartlett; Robert Chen; Michelle A Fanale; Pauline Brice; Ajay Gopal; Scott E Smith; Ranjana Advani; Jeffrey V Matous; Radhakrishnan Ramchandren; Joseph D Rosenblatt; Dirk Huebner; Pamela Levine; Laurie Grove; Andres Forero-Torres
Journal:  J Hematol Oncol       Date:  2014-03-19       Impact factor: 17.388
View more
  7 in total

Review 1.  CD30+ Lymphoproliferative Disorders of the Skin.

Authors:  Maxwell B Sauder; John T O'Malley; Nicole R LeBoeuf
Journal:  Hematol Oncol Clin North Am       Date:  2017-04       Impact factor: 3.722

2.  Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.

Authors:  Ying Chen; Fengtao You; Licui Jiang; Jialu Li; Xuejun Zhu; Yangyi Bao; Xiang Sun; Xiaowen Tang; Huimin Meng; Gangli An; Bozhen Zhang; Lin Yang
Journal:  Oncotarget       Date:  2017-06-06

Review 3.  Novel targeted therapies of T cell lymphomas.

Authors:  Katarzyna Iżykowska; Karolina Rassek; Dorota Korsak; Grzegorz K Przybylski
Journal:  J Hematol Oncol       Date:  2020-12-31       Impact factor: 17.388

Review 4.  The role of trogocytosis in immune surveillance of Hodgkin lymphoma.

Authors:  Qun Zeng; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2020-06-17       Impact factor: 8.110

5.  The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through G1.

Authors:  Jingxi Zhang; Zuoqiao Wu; Anton Savin; Mihye Yang; Ying-Han R Hsu; Eugeniu Jantuan; Julinor T C Bacani; Robert J Ingham
Journal:  Sci Rep       Date:  2018-10-30       Impact factor: 4.379

6.  Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.

Authors:  Markus Tiemann; Vera Samoilova; Dmitri Atiakshin; Igor Buchwalow
Journal:  BMC Res Notes       Date:  2020-03-07

7.  Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma.

Authors:  Mengmeng Pan; Pingping Yang; Fangce Wang; Xiu Luo; Bing Li; Yi Ding; Huina Lu; Yan Dong; Wenjun Zhang; Bing Xiu; Aibin Liang
Journal:  Front Genet       Date:  2021-06-09       Impact factor: 4.599
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.